241 related articles for article (PubMed ID: 35565385)
1. Clinical Significance of Molecular Alterations and Systemic Therapy for Meningiomas: Where Do We Stand?
Pellerino A; Bruno F; Palmiero R; Pronello E; Bertero L; Soffietti R; Rudà R
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565385
[TBL] [Abstract][Full Text] [Related]
2. New molecular targets in meningiomas: the present and the future.
Venur VA; Santagata S; Galanis E; Brastianos PK
Curr Opin Neurol; 2018 Dec; 31(6):740-746. PubMed ID: 30379704
[TBL] [Abstract][Full Text] [Related]
3. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S
Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201
[TBL] [Abstract][Full Text] [Related]
5. Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas.
Strickland MR; Gill CM; Nayyar N; D'Andrea MR; Thiede C; Juratli TA; Schackert G; Borger DR; Santagata S; Frosch MP; Cahill DP; Brastianos PK; Barker FG
J Neurosurg; 2017 Aug; 127(2):438-444. PubMed ID: 27885953
[TBL] [Abstract][Full Text] [Related]
6. Genetic characterization and mutational profiling of foramen magnum meningiomas: a multi-institutional study.
Hua L; Alkhatib M; Fujio S; Alhasan B; Herold S; Zeugner S; Zolal A; Hijazi MM; Clark VE; Wakimoto H; Shankar GM; Brastianos PK; Barker FG; Cahill DP; Ren L; Eyüpoglu IY; Gong Y; Schackert G; Juratli TA
J Neurosurg; 2024 Jan; ():1-7. PubMed ID: 38277657
[TBL] [Abstract][Full Text] [Related]
7. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
[TBL] [Abstract][Full Text] [Related]
8. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
[TBL] [Abstract][Full Text] [Related]
9. Meningioma: Molecular Updates from the 2021 WHO Classification of CNS Tumors and Imaging Correlates.
Soni N; Ora M; Bathla G; Szekeres D; Desai A; Pillai J; Agarwal A
AJNR Am J Neuroradiol; 2024 Jun; ():. PubMed ID: 38844366
[TBL] [Abstract][Full Text] [Related]
10. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.
Jungwirth G; Warta R; Beynon C; Sahm F; von Deimling A; Unterberg A; Herold-Mende C; Jungk C
Acta Neuropathol Commun; 2019 Aug; 7(1):140. PubMed ID: 31470906
[TBL] [Abstract][Full Text] [Related]
11. Genetic landscape of meningioma.
Yuzawa S; Nishihara H; Tanaka S
Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
[TBL] [Abstract][Full Text] [Related]
12. Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets.
Maggio I; Franceschi E; Di Nunno V; Gatto L; Tosoni A; Angelini D; Bartolini S; Lodi R; Brandes AA
Diagnostics (Basel); 2021 Oct; 11(10):. PubMed ID: 34679551
[TBL] [Abstract][Full Text] [Related]
13. High-grade meningiomas: biology and implications.
Bi WL; Prabhu VC; Dunn IF
Neurosurg Focus; 2018 Apr; 44(4):E2. PubMed ID: 29606053
[TBL] [Abstract][Full Text] [Related]
14. Molecular alterations in meningioma: prognostic and therapeutic perspectives.
Birzu C; Peyre M; Sahm F
Curr Opin Oncol; 2020 Nov; 32(6):613-622. PubMed ID: 32890025
[TBL] [Abstract][Full Text] [Related]
15. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
[TBL] [Abstract][Full Text] [Related]
16. A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base.
Martinez NL; Khanna O; Farrell CJ
Chin Clin Oncol; 2020 Dec; 9(6):75. PubMed ID: 32819111
[TBL] [Abstract][Full Text] [Related]
17. Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent
Williams SR; Juratli TA; Castro BA; Lazaro TT; Gill CM; Nayyar N; Strickland MR; Babinski M; Johnstone SE; Frosch MP; Silverman IM; Ely HA; Kaplan AB; D'Andrea MR; Bihun IV; Hoang K; Batchelor E; Christiansen J; Cahill DP; Barker FG; Brastianos PK
J Neurol Surg B Skull Base; 2019 Dec; 80(6):562-567. PubMed ID: 31750041
[No Abstract] [Full Text] [Related]
18. [The Potential of Personalized/Precision Medicine for Meningiomas].
Yamaguchi S; Fujimura M
No Shinkei Geka; 2022 Jan; 50(1):132-140. PubMed ID: 35169093
[TBL] [Abstract][Full Text] [Related]
19. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.
Shankar GM; Abedalthagafi M; Vaubel RA; Merrill PH; Nayyar N; Gill CM; Brewster R; Bi WL; Agarwalla PK; Thorner AR; Reardon DA; Al-Mefty O; Wen PY; Alexander BM; van Hummelen P; Batchelor TT; Ligon KL; Ligon AH; Meyerson M; Dunn IF; Beroukhim R; Louis DN; Perry A; Carter SL; Giannini C; Curry WT; Cahill DP; Barker FG; Brastianos PK; Santagata S
Neuro Oncol; 2017 Apr; 19(4):535-545. PubMed ID: 28170043
[TBL] [Abstract][Full Text] [Related]
20. Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker.
Parada CA; Osbun JW; Busald T; Karasozen Y; Kaur S; Shi M; Barber J; Adidharma W; Cimino PJ; Pan C; Gonzalez-Cuyar LF; Rostomily R; Born DE; Zhang J; Ferreira M
Clin Cancer Res; 2020 Jan; 26(1):193-205. PubMed ID: 31615938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
